Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUPRENZA vs FASTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.
Management of moderate to severe chronic pain,Off-label: Treatment of opioid use disorder (as a maintenance therapy similar to buprenorphine)
Short-term adjunct in exogenous obesity,Off-label: Attention deficit hyperactivity disorder (ADHD)
Adults: 200 mg orally twice daily with meals.
30 mg orally once daily in the morning, administered as a single dose.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
Terminal elimination half-life is approximately 16-20 hours for the immediate-release formulation. With sustained-release forms, effective half-life may extend to 24-34 hours due to prolonged absorption. Clinical context: time to reach steady state is about 3-5 days.
Primarily hepatic via CYP3A4 and CYP3A5 to norbuprenorphine (active metabolite); also undergoes glucuronidation.
Hepatic metabolism via CYP3A4 and CYP2D6; active metabolite phendimetrazine (for some formulations).
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
Primarily renal (approximately 70-80% unchanged) and biliary/fecal (20-30% as metabolites). Urinary excretion is p H-dependent; acidic urine increases elimination.
Approximately 95-98% bound to plasma proteins, primarily albumin.
Approximately 40-50% bound to plasma proteins (albumin).
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
Approximately 3-5 L/kg. High Vd indicates extensive tissue distribution, including brain.
Oral bioavailability is approximately 70-80%.
Oral immediate-release: ~90% (high first-pass metabolism; absolute bioavailability is lower, but systemic exposure is adequate). Oral sustained-release: similar extent but with prolonged absorption.
e GFR <45 m L/min/1.73m²: contraindicated. e GFR ≥45: no adjustment.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²). For moderate impairment (e GFR 30-59 m L/min/1.73 m²), reduce dose to 15 mg once daily.
Child-Pugh Class A: no adjustment; Class B: reduce to 200 mg once daily; Class C: contraindicated.
Contraindicated in Child-Pugh class C cirrhosis. In Child-Pugh class A or B, initiate at 15 mg once daily and titrate cautiously to maximum 30 mg once daily.
Not recommended for patients under 18 years; safety and efficacy not established.
Not recommended for pediatric patients under 16 years of age due to lack of safety and efficacy data.
No specific dose adjustment; monitor renal function and use caution due to increased risk of adverse effects.
Initiating at 15 mg once daily is recommended due to increased sensitivity and potential for central nervous system adverse effects; maximum dose 30 mg once daily.
Risk of respiratory depression, especially in non-opioid-tolerant patients. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of serious injury or death due to accidental exposure in children.
None.
Respiratory depression, particularly in the first 24-72 hours of treatment; caution in patients with pulmonary disease. Risk of QT prolongation. Adrenal insufficiency. Severe hypotension. Risk of misuse, abuse, and addiction. Tolerance and physical dependence.
Cardiovascular events (hypertension, tachycardia, stroke), psychiatric adverse effects (psychosis, dependence), primary pulmonary hypertension, valvular heart disease, tolerance, withdrawal symptoms, glaucoma, hyperthyroidism, seizure disorder, diabetes (dose adjustment required), elderly patients (higher sensitivity).
Hypersensitivity to buprenorphine or any component of the formulation. Severe respiratory insufficiency. Acute or severe bronchial asthma. Gastrointestinal obstruction, including paralytic ileus.
Cardiovascular disease (e.g., coronary artery disease, arrhythmias, hypertension), hyperthyroidism, glaucoma, agitated states, history of drug abuse, MAOIs (concurrent or within 14 days), hypersensitivity to sympathomimetics.
No significant food interactions. Grapefruit juice may increase buprenorphine levels; avoid large quantities.
Avoid excessive caffeine intake (e.g., coffee, tea, cola, energy drinks) as it may potentiate CNS and cardiovascular effects. Grapefruit juice may alter drug metabolism; avoid concurrent consumption. Maintain a balanced, reduced-calorie diet as part of the weight loss plan. Alcohol should be avoided due to potential additive CNS effects.
Supr ENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: risk of continued virilization, including phallic enlargement and ambiguous genitalia. Fetal growth restriction may occur.
FDA Pregnancy Category X. First trimester: Increased risk of oral clefts and cardiac malformations with amphetamine use. Second and third trimesters: Risk of premature delivery, low birth weight, and neonatal withdrawal syndrome. Avoid use in pregnancy.
Testosterone is present in breast milk; M/P ratio not reported. Avoid breastfeeding due to potential for androgenization of the infant. Use only if clearly needed and no safer alternative.
Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infants (irritability, poor feeding). Contraindicated during breastfeeding.
Not applicable; Supr ENza is contraindicated in pregnancy. No dose adjustments are recommended as use is avoided entirely.
Contraindicated in pregnancy; no dose adjustments recommended.
SUPRENZA (buprenorphine/naloxone) sublingual film is used for opioid dependence. Monitor for respiratory depression especially when combined with benzodiazepines or alcohol. The naloxone component is poorly absorbed sublingually but precipitates withdrawal if injected. Administer only after clear signs of withdrawal to avoid precipitated withdrawal. Adjust dose in hepatic impairment as buprenorphine is hepatically metabolized.
Fastin (phentermine) is a sympathomimetic amine indicated for short-term (up to 12 weeks) monotherapy for obesity. It should be used in conjunction with a reduced-calorie diet and exercise. Avoid co-administration with MAOIs or within 14 days of MAOI use due to hypertensive crisis risk. Use with caution in patients with hypertension, diabetes, or history of drug abuse. Monitor blood pressure and heart rate regularly. Tachyphylaxis may develop; discontinue if tolerance occurs. Do not use in patients with advanced arteriosclerosis, hyperthyroidism, glaucoma, or agitated states.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Place film under the tongue until fully dissolved; do not chew or swallow.,Avoid alcohol and benzodiazepines as they can cause severe respiratory depression.,Keep out of reach of children; accidental exposure can be fatal.,Do not abruptly stop; withdrawal symptoms may occur.,Store at room temperature away from moisture and heat.
Take Fastin exactly as prescribed, usually once daily in the morning to avoid insomnia.,Do not crush or chew the extended-release capsule; swallow whole.,Avoid taking late in the day to prevent difficulty sleeping.,Report any chest pain, palpitations, shortness of breath, or dizziness immediately.,Do not increase dose or take more frequently than prescribed; risk of dependence and side effects.,Fastin is for short-term use only (up to 12 weeks) and should be combined with a reduced-calorie diet and exercise.,Do not use if you have taken an MAO inhibitor in the last 14 days.,Avoid alcohol and other CNS stimulants (e.g., caffeine in large amounts) as they may increase side effects.,Do not stop abruptly; follow your doctor's instructions for tapering off.,Keep out of reach of children; misuse can cause severe cardiac toxicity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUPRENZA vs FASTIN, answered by our medical review team.
SUPRENZA is a Sympathomimetic Anorectic that works by Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.. FASTIN is a Sympathomimetic Anorectic that works by Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUPRENZA and FASTIN depend on the specific clinical indication. These are both Sympathomimetic Anorectic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUPRENZA is: Adults: 200 mg orally twice daily with meals.. The standard adult dose of FASTIN is: 30 mg orally once daily in the morning, administered as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUPRENZA and FASTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUPRENZA is classified as Category C. SuprENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnorm. FASTIN is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of oral clefts and cardiac malformations with amphetamine use. Second and third trimesters: Risk of premature delivery, lo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.